Recent advances in the phencyclidine model of schizophrenia
- PMID: 1654746
- DOI: 10.1176/ajp.148.10.1301
Recent advances in the phencyclidine model of schizophrenia
Abstract
Objective: Phencyclidine (PCP, "angel dust") induces a psychotomimetic state that closely resembles schizophrenia. As opposed to amphetamine-induced psychosis, PCP-induced psychosis incorporates both positive (e.g., hallucinations, paranoia) and negative (e.g., emotional withdrawal, motor retardation) schizophrenic symptoms. PCP-induced psychosis also uniquely incorporates the formal thought disorder and neuropsychological deficits associated with schizophrenia. The purpose of the present paper is to review recent advances in the study of the molecular mechanisms of PCP action and to describe their implications for the understanding of schizophrenic pathophysiology.
Method: Twenty-five papers were identified that described the clinical dose and serum and CSF levels at which PCP induces its psychotomimetic effects. The dose range of PCP-induced effects were compared to the dose range at which PCP interacts with specific molecular targets and affects neurotransmission.
Results: It was found that PCP-induced psychotomimetic effects are associated with submicromolar serum concentrations of PCP. At these concentrations PCP interacts selectively with a specific binding site (PCP receptor) that is associated with the N-methyl-D-aspartate (NMDA)-type excitatory amino acid receptor. Occupation of its receptor by PCP induces noncompetitive inhibition of NMDA receptor-mediated neurotransmission. Other NMDA antagonists such as the dissociative anesthetic ketamine induce PCP-like neurobehavioral effects in proportion to their potency in binding to the PCP receptor and inducing NMDA receptor inhibition.
Conclusions: These findings suggest that endogenous dysfunction of NMDA receptor-mediated neurotransmission might contribute to the pathogenesis of schizophrenia. The relative implications of the PCP and amphetamine models of schizophrenia are discussed in relationship to the diagnosis and etiology of schizophrenia.
Comment in
-
Phencyclidine and schizophrenia.Am J Psychiatry. 1992 Jun;149(6):848-9. Am J Psychiatry. 1992. PMID: 1350430 No abstract available.
Similar articles
-
Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.Ann N Y Acad Sci. 2006 Nov;1086:160-8. doi: 10.1196/annals.1377.003. Ann N Y Acad Sci. 2006. PMID: 17185514 Review.
-
Interaction of L-glutamate and magnesium with phencyclidine recognition sites in rat brain: evidence for multiple affinity states of the phencyclidine/N-methyl-D-aspartate receptor complex.Mol Pharmacol. 1987 Dec;32(6):820-30. Mol Pharmacol. 1987. PMID: 2892125
-
Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.Methods Find Exp Clin Pharmacol. 2007 May;29(4):291-301. doi: 10.1358/mf.2007.29.4.1075358. Methods Find Exp Clin Pharmacol. 2007. PMID: 17609743 Review.
-
Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801.Behav Brain Res. 2009 Dec 7;204(2):410-5. doi: 10.1016/j.bbr.2009.02.007. Epub 2009 Feb 14. Behav Brain Res. 2009. PMID: 19716985
-
Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia.Neurochem Int. 2019 May;125:1-6. doi: 10.1016/j.neuint.2019.02.001. Epub 2019 Feb 5. Neurochem Int. 2019. PMID: 30731185 Review.
Cited by
-
Correlation between desynchrony of hippocampal neural activity and hyperlocomotion in the model mice of schizophrenia and therapeutic effects of aripiprazole.CNS Neurosci Ther. 2024 May;30(5):e14739. doi: 10.1111/cns.14739. CNS Neurosci Ther. 2024. PMID: 38702935 Free PMC article.
-
A computational account of the development and evolution of psychotic symptoms.ArXiv [Preprint]. 2024 Apr 16:arXiv:2404.10954v1. ArXiv. 2024. PMID: 38699166 Free PMC article. Preprint.
-
Associations among plasma markers for N-methyl-d-aspartate receptor hypofunction, redox dysregulation, and insufficient myelination in patients with schizophrenia.Heliyon. 2024 Apr 25;10(9):e30193. doi: 10.1016/j.heliyon.2024.e30193. eCollection 2024 May 15. Heliyon. 2024. PMID: 38694089 Free PMC article.
-
Novel α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) potentiator LT-102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia.CNS Neurosci Ther. 2024 Apr;30(4):e14713. doi: 10.1111/cns.14713. CNS Neurosci Ther. 2024. PMID: 38615362 Free PMC article.
-
Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?Eur Arch Psychiatry Clin Neurosci. 2024 Feb 27. doi: 10.1007/s00406-024-01770-7. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 38411629 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials